ArticleJournal of market access & health policy2020

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany.

S Wahler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.